Psilocybin may be effective for treatment-resistant depression
Pharmaceutical journal/The pharmaceutical journal 2022 DOI: 10.1211/pj.2022.1.164911 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Phase II trial Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Intervention | Psilocybin |
| Dose | 25 mg |
| Topics | Depression Psilocybin |
| Keywords | Depression economics Psychotherapist Hallucinogen Keynesian economics |
| Key findings | A single 25mg dose of psilocybin with psychological support may improve symptoms of treatment-resistant depression. |
Abstract
The largest trial to date of the psychedelic drug psilocybin has shown that, alongside psychological support, a single 25mg dose may improve the symptoms of treatment-resistant depression. The phase II study, published in the New England Journal of Medicine on 3 November 2022, was conducted across 22 sites in 10 countries, including the UK, between […]